Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00145301
Status:
COMPLETED
Last Update Posted:
2012-05-21
First Post:
2005-09-01
Brief Title:
52 Week International Multi-center Randomized Double-blind Double-dummy Parallel-group Clinical Trial to Compare Retention on Treatment Safety Tolerability Efficacy of Lumiracoxib 100 mg od Lumiracoxib 100 mg Bid Celecoxib 200 mg od in Pts With Primary OA of Hip Knee Hand or Spine
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 52-week International Multi-center Randomized Double-blind Double-dummy Parallel-group Clinical Trial to Compare Retention on Treatment Safety Tolerability and Efficacy of Lumiracoxib 100 mg od Lumiracoxib 100 mg Bid and Celecoxib 200 mg od in Patients With Primary Osteoarthritis of Hip Knee Hand or Spine
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will compare the retention on treatment based on the rate of patients staying on treatment for 1 year of patients suffering from primary osteoarthritis using two different doses of lumiracoxib 100 mg od or 100 mg bid or using celecoxib 200 mg od
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None